Bacterial Infections

Following three studies that examined its safety and efficacy, the FDA approves the first fecal microbiota product to prevent recurring Clostridioides difficle infection in patients.

The new antibacterial drug was approved after it was proven safe and effective in a study of 448 patients with complicated UTIs.

After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.

A new 3-drug antibacterial drug injection containing an FDA-approved antibiotic and a new β-lactamase inhibitor has been approved.

In an FDA statement, Scott Gotlieb, MD, discusses the pathogen added to the list of foodborne pathogens to routinely test for, why it was added, and the FDA’s ongoing efforts to screen domestic and imported...

The FDA has approved a new injectable fluorocycline antibiotic for the treatment of complicated intraabdominal infections.

The FDA has expanded the indication for a drug formerly approved for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections.

The US Food and Drug Administration has approved a new option for the treatment of bacterial vaginosis in adult women.

The US Food and Drug Administration has approved a new treatment option for adult patients with complicated urinary tract infections, including pyelonephritis.